Skyscape Web Viewer : Cancer Pharmacology: An Illustrated Manual of Anticancer Drugs : Main Index

View All
MAC
prostate cancer abiraterone and its prodrug, abiraterone acetate and rogen receptor (AR) activation by dihydrotestosterone (DHT) AR antagonists (antiand rogens) enzalutamide overview steroidal and nonsteroidal antiand rogens 17α-hydroxylase/17-lyase (CYP17) inhibitors and rogen deprivation therapy apalutamide darolutamide GnRH agonists and antagonists schematic structure of GnRH agonist relative to native GnRH treatment goal
mammalian target of rapamycin (mTOR) Hormonal Therapies Alone and in Combinations for Treatment of Breast Cancer Transplant-Related Agents
mantle cell lymphoma (MCL) Answer 11.5 Targeted Therapies (Small Molecules) DNA Repair, Apoptotic Pathways, CDK Inhibitors
marginal zone lymphoma (MZL) Answer 11.5 Targeted Therapies (Small Molecules)
maximal tolerated dose (MTD) Answer 16.1 Question 16.2 Drug Approval and Regulatory Issues
MCL
MDSCs
Mel
membrane attack complex (MAC)
Me-THF
methotrexate (MTX) Answer 4.2 Answer 4.5 Question 4.2 Question 4.4 Answer 4.1 Answer 4.3 Antimetabolites: Antifolates Question 4.3 Question 4.5
methylenetetrahydrofolate (Me-THF)
microsatellite instability (MSI)
minimal residual disease (MRD) Immunotherapeutics Including Vaccines, Bispecifics, CAR-T, and Checkpoint Inhibitors Answer 13.1
mitogen-activated protein kinase (MAPK)
Mabs
MAPK
maximum plasma concentration (Cmax)
MDR
MDSs
melphalan (Mel)
MESNA
MGMT
mismatch repair deficiency (MMRd)
MM
MMF
molecular pharmacological audit trial (MoPhAT)
monoclonal antibodies (Mabs) class and target Monoclonal Antibodies Including Immunoconjugates and Cytokine-Directed Agents naked prevention and management of infusion-related reactions radioimmunoconjugates uses Answer 12.1 drug conjugates Multiple Myeloma as a Paradigm for Multi-Targeted Intervention overview Question 12.1 structure and classification
MoPhAT